MayoComplete Kidney Cancer Panel, Next-Generation Sequencing, Tumor

Clinical Use

Use

This test is useful for identifying specific mutations to assist in tumor diagnosis/classification, assisting in the clinical management of patients with renal cell carcinoma, and assessing microsatellite instability for immunotherapy decisions. This panel evaluates formalin-fixed, paraffin-embedded tumor or cytology slides from patients with kidney carcinoma for gene mutations to identify candidates for targeted therapy. It also evaluates mismatch repair genes and microsatellite instability (MSI) status, which is clinically actionable for determining the efficacy of immunotherapy in solid tumors.

Special Instructions

Not provided.

Limitations

This test does not differentiate between somatic and germline alterations, and additional testing may be necessary for hereditary risk clarification. It may not detect multi-exon deletions, larger-scale genomic copy number variants, copy neutral loss of heterozygosity, or epigenetic modifications. DNA variants of uncertain significance may be identified, and negative results do not exclude variants below detection limits. Proper interpretation relies on adequate specimen handling and processing.

Test Details

New York Approved